Liver cancer treatment cost in Israel ranges from $22,000 to $40,000 for surgical removal, while essential diagnostics like a PET/CT scan run from $1,300 to $1,800. Total expenses depend on the cancer stage, the use of robotic technology, and the hospital type. International patients typically save 30–80% compared to the United States. Premier care is centered in Tel Aviv, Jerusalem, and Haifa.
Typical Liver Cancer Treatment Costs in Israel
Bookimed Expert Insight: Patients seeking high success rates should prioritize JCI-accredited centers like Sourasky Medical Center, which reports a 90% oncology success rate. For those requiring complex GI interventions, Forbes-listed experts like Dr. Menahem Ben-haim offer specialized surgical expertise. Private options like Assuta Medical Center provide the most flexibility, allowing patients to select their specific surgeon and room type for a personalized experience.
| Israel | Turkey | Austria | |
| Removal of liver cancer | from $22,000 | from $10,800 | from $40,000 |
| Radiofrequency ablation of the liver | from $9,500 | from $3,500 | from $12,000 |
| Proton-beam therapy | from $48,000 | from $70,000 | from $80,000 |
| NanoKnife | from $18,500 | from $9,500 | from $25,000 |
| CyberKnife | from $17,500 | from $4,750 | from $50,000 |
Prof. Merimsky heads the sarcoma unit at Sourasky Medical Center, bringing deep expertise in liver cancer treatment with 41 years of experience of experience.
Dr. Pelles Sharon specializes in advanced liver cancer treatments at Sourasky Medical Center, including chemotherapy and targeted therapies. She actively contributes to oncological research, ensuring evidence-based patient care.
Prof. Arber specializes in preventing and diagnosing GI cancers, not just treating them. He runs the Cancer Prevention Center at Sourasky Medical Center.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Written by Halina Shubala